{'fraction_non_alphanumeric': 0.018842530282637954, 'fraction_numerical': 0.0, 'mean_word_length': 5.953271028037383, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Diffuse brachial plexopathy after interscalene blockade in a patient receiving cisplatin chemotherapy: the pharmacologic double crush syndrome.

Cisplatin is an alkylating chemotherapeutic drug commonly used in patients with testicular, ovarian, and bladder malignancies, osteogenic sarcoma, and head/neck squamous cell and small cell lung carcinomas. Renal dysfunction, acoustic nerve damage, and a sensory peripheral neuropathy are among the most common and detrimental toxic side effects. The safety of performing regional anesthetic techniques in patients exposed to cisplatin has not been previously reported. We present a case of a severe, diffuse brachial plexopathy after interscalene blockade in a patient receiving cisplatin therapy.